DOI:
10.1055/s-00000034
Klinische Pädiatrie
LinksClose Window
References
Banerjee A, Jakacki RI, Onar-Thomas A. et al.
A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study.
Neuro-oncology 2017;
19: 1135-1144
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.